One connector, four scholarly indexes, real DOIs and legal free PDFs. Works in Claude and ChatGPT.
Paste it into Claude or ChatGPT as a custom connector. 3-day free trial.
Nick Andrews, Julia Stowe, Freja Kirsebom, S Toffa, Tim Rickeard, Eileen Gallagher, Charlotte Gower, Meaghan M. Kall, Natalie Groves, Anne-Marie O’Connell and 21 more
BACKGROUND: A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly vaccinated populations has aroused concerns about the effectiveness of current vaccines. METHODS: We used a test-negative case-control design to estimate vaccine effectiveness against symptomatic disease caused by the omicron and delta (B.1.617.2) variants in England. Vaccine effectiveness was calculated after primary immunization with two doses of BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCoV-19 (AstraZeneca), or mRNA-1273 (Moderna) vaccine and after a booster dose of BNT162b2, ChAdOx1 nCoV-19, or mRNA-1273. RESULTS: Between November 27, 2021, and January 12, 2022, a total of 886,774 eligible persons infected with the omicron variant, 204,154 eligible persons infected with the delta variant, and 1,572,621 eligible test-negative controls were identified. At all time points investigated and for all combinations of primary course and booster vaccines, vaccine effectiveness against symptomatic disease was higher for the delta variant than for the omicron variant. No effect against the omicron variant was noted from 20 weeks after two ChAdOx1 nCoV-19 doses, whereas vaccine effectiveness after two BNT162b2 doses was 65.5% (95% confidence interval [CI], 63.9 to 67.0) at 2 to 4 weeks, dropping to 8.8% (95% CI, 7.0 to 10.5) at 25 or more weeks. Among ChAdOx1 nCoV-19 primary course recipients, vaccine effectiveness increased to 62.4% (95% CI, 61.8 to 63.0) at 2 to 4 weeks after a BNT162b2 booster before decreasing to 39.6% (95% CI, 38.0 to 41.1) at 10 or more weeks. Among BNT162b2 primary course recipients, vaccine effectiveness increased to 67.2% (95% CI, 66.5 to 67.8) at 2 to 4 weeks after a BNT162b2 booster before declining to 45.7% (95% CI, 44.7 to 46.7) at 10 or more weeks. Vaccine effectiveness after a ChAdOx1 nCoV-19 primary course increased to 70.1% (95% CI, 69.5 to 70.7) at 2 to 4 weeks after an mRNA-1273 booster and decreased to 60.9% (95% CI, 59.7 to 62.1) at 5 to 9 weeks. After a BNT162b2 primary course, the mRNA-1273 booster increased vaccine effectiveness to 73.9% (95% CI, 73.1 to 74.6) at 2 to 4 weeks; vaccine effectiveness fell to 64.4% (95% CI, 62.6 to 66.1) at 5 to 9 weeks. CONCLUSIONS: Primary immunization with two doses of ChAdOx1 nCoV-19 or BNT162b2 vaccine provided limited protection against symptomatic disease caused by the omicron variant. A BNT162b2 or mRNA-1273 booster after either the ChAdOx1 nCoV-19 or BNT162b2 primary course substantially increased protection, but that protection waned over time. (Funded by the U.K. Health Security Agency.).
Formatted from the source metadata, not typed by hand. For a whole reference list, use the citation generator or ask your assistant through Find Research.
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M. M., Groves, N., O’Connell, A.-M., Simons, D., Blomquist, P. B., Zaidi, A., Nash, S., Aziz, N. I. B. A., Thelwall, S., Dabrera, G., Myers, R. E., Amirthalingam, G., … Bernal, J. L. (2022). Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. New England Journal of Medicine, 386(16), 1532–1546. https://doi.org/10.1056/nejmoa2119451
Andrews, Nick, et al. "Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant." New England Journal of Medicine, vol. 386, no. 16, 2022, pp. 1532–1546, https://doi.org/10.1056/nejmoa2119451.
Andrews, Nick, Julia Stowe, Freja Kirsebom, S Toffa, Tim Rickeard, Eileen Gallagher, Charlotte Gower, et al. "Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant." New England Journal of Medicine 386, no. 16 (2022): 1532–1546. https://doi.org/10.1056/nejmoa2119451.
Andrews N., Stowe J., Kirsebom F. [и др.] Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant // New England Journal of Medicine. — 2022. — Vol. 386, № 16. — P. 1532–1546. — URL: https://doi.org/10.1056/nejmoa2119451
@article{andrews2022covid,
title = {{Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant}},
author = {Nick Andrews and Julia Stowe and Freja Kirsebom and S Toffa and Tim Rickeard and Eileen Gallagher and Charlotte Gower and Meaghan M. Kall and Natalie Groves and Anne-Marie O’Connell and David Simons and Paula Bianca Blomquist and Asad Zaidi and Sophie Nash and Nurin Iwani Binti Abdul Aziz and Simon Thelwall and Gavin Dabrera and Richard E. Myers and Gayatri Amirthalingam and Saheer Gharbia and Jeffrey C. Barrett and Richard Elson and Shamez N Ladhani and Neil Ferguson and Maria Zambon and Colin Campbell and Kevin Brown and Susan Hopkins and Meera A Chand and Mary Ramsay and Jamie Lopez Bernal},
journal = {New England Journal of Medicine},
year = {2022},
volume = {386},
number = {16},
pages = {1532--1546},
doi = {10.1056/nejmoa2119451},
url = {https://doi.org/10.1056/nejmoa2119451}
}TY - JOUR AU - Andrews, Nick AU - Stowe, Julia AU - Kirsebom, Freja AU - Toffa, S AU - Rickeard, Tim AU - Gallagher, Eileen AU - Gower, Charlotte AU - Kall, Meaghan M. AU - Groves, Natalie AU - O’Connell, Anne-Marie AU - Simons, David AU - Blomquist, Paula Bianca AU - Zaidi, Asad AU - Nash, Sophie AU - Aziz, Nurin Iwani Binti Abdul AU - Thelwall, Simon AU - Dabrera, Gavin AU - Myers, Richard E. AU - Amirthalingam, Gayatri AU - Gharbia, Saheer AU - Barrett, Jeffrey C. AU - Elson, Richard AU - Ladhani, Shamez N AU - Ferguson, Neil AU - Zambon, Maria AU - Campbell, Colin AU - Brown, Kevin AU - Hopkins, Susan AU - Chand, Meera A AU - Ramsay, Mary AU - Bernal, Jamie Lopez TI - Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant JO - New England Journal of Medicine VL - 386 IS - 16 SP - 1532 EP - 1546 PY - 2022 DA - 2022/03/02 DO - 10.1056/nejmoa2119451 UR - https://doi.org/10.1056/nejmoa2119451 ER -
Add Find Research to Claude or ChatGPT and ask in plain language. The assistant reads this record, finds the papers around it and cites only what it actually found:
Setup takes about a minute: add the connector, then start the free trial.
Record from OpenAlex; open-access location from Unpaywall and the indexes. Find Research links only to legal copies.